Tirzepatide
approvedAlso known as: Mounjaro, Zepbound, LY3298176
**Mechanism of Action** Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique mechanism enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety. The synergistic activation of both receptors results in superior glycemic control and weight reduction compared to selective GLP-1 receptor agonists alone. **Key Research Findings** Clinical trials (e.g., SURPASS and SURMOUNT programs) demonstrate that tirzepatide significantly reduces HbA1c (up to 2.4% from baseline) and body weight (up to 22.5% at the highest dose) in patients with type 2 diabetes and obesity. Head-to-head studies show greater efficacy versus semaglutide and insulin glargine. Common adverse effects include gastrointestinal events (nausea, diarrhea), which are dose-dependent and typically transient. **Clinical Relevance** Approved by the FDA (2022 for type 2 diabetes as Mounjaro; 2023 for chronic weight management as Zepbound), tirzepatide is a first-in-class dual incretin agonist. It offers a potent option for patients requiring substantial glycemic and weight control, with ongoing research into cardiovascular outcomes and non-alcoholic steatohepatitis (NASH). For research purposes only — not medical advice.
Key data
C225H348N48O68Research & studies
Mean weight change from week 36 to 88 was -5.5% with tirzepatide vs +14.0% with placebo (difference -19.4%).; 89.5% of tirzepatide-treated participants maintained ≥80% of lead-in weight loss vs 16.6% on placebo.; Overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide vs 9.9% for placebo.; Withdrawing tirzepatide led to substantial weight regain, while continued treatment maintained and augmented initial reduction.
13,299 participants were randomized across 640 sites in 30 countries.; Mean baseline age was 64.1 years, diabetes duration 14.7 years, HbA1c 8.4%, and BMI 32.6 kg/m².; 65.0% had coronary disease, 19.1% prior stroke, and 25.3% peripheral artery disease.; The primary outcome is time to first MACE (CV death, myocardial infarction, or stroke), with noninferiority margin of upper confidence limit <1.05.
Frequently asked questions
What is Tirzepatide?
**Mechanism of Action** Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique mechanism enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric empty
How does Tirzepatide work?
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
What is the research status of Tirzepatide?
Tirzepatide is currently classified as approved, with 2,111 research references on record. This is for research purposes only and is not medical advice.
What is the half-life of Tirzepatide?
The reported half-life of Tirzepatide is ~5 days.
What is the molecular weight of Tirzepatide?
Tirzepatide has a molecular weight of approximately 4813 g/mol (formula C225H348N48O68).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
Amylin analog adjunct to insulin that slows gastric emptying, suppresses glucagon, and increases satiety.
Build on Tirzepatide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key